Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,460 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
12.9
Industry P/E
--
EV/EBITDA
-6.6
Div. Yield
0 %
Debt to Equity
0.3
Book Value
$--
EPS
$-2
Face value
--
Shares outstanding
97,219,193
CFO
$-185.63 Mln
EBITDA
$-291.57 Mln
Net Profit
$-273.50 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mind Medicine Inc (MNMD)
| 17.6 | 13.5 | 29.7 | 85.1 | 60.8 | -23.5 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Mind Medicine Inc (MNMD)
| 92.4 | 66.4 | -89.4 | -54.8 | 573.7 | 26.9 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mind Medicine Inc (MNMD)
|
15.8 | 1,460.2 | 0.0 | -168.1 | -- | -95.1 | -- | 12.9 |
| 70.6 | 669.9 | 0.0 | -19.8 | -- | -28.1 | -- | 10.8 | |
| 5.2 | 413.1 | 0.0 | -131.6 | -- | -61.8 | -- | 1.0 | |
| 9.6 | 5.8 | 14.5 | -4.4 | -28.0 | -11.8 | -- | 0.3 | |
| 1.0 | 86.6 | 0.0 | -35.3 | -- | -1067.3 | -- | 1,236.3 |
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety... disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. Read more
CEO & Director
Mr. Robert Barrow
CEO & Director
Mr. Robert Barrow
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Mind Medicine Inc (MNMD) is $15.75 (NASDAQ) as of 13-Feb-2026 09:30 EDT. Mind Medicine Inc (MNMD) has given a return of 60.77% in the last 3 years.
Since, TTM earnings of Mind Medicine Inc (MNMD) is negative, P/E ratio is not available.
The P/B ratio of Mind Medicine Inc (MNMD) is 12.91 times as on 13-Feb-2026, a 321 premium to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-5.38
|
2.42
|
|
2023
|
-1.54
|
1.89
|
|
2022
|
-1.47
|
0.55
|
|
2021
|
-0.42
|
0.26
|
|
2020
|
-2.32
|
1.04
|
The 52-week high and low of Mind Medicine Inc (MNMD) are Rs 16.65 and Rs 4.70 as of 02-Apr-2026.
Mind Medicine Inc (MNMD) has a market capitalisation of $ 1,460 Mln as on 13-Feb-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Mind Medicine Inc (MNMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.37
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.